DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.
DuPont will pay a fine of $1.275M to settle a federal complaint over eight chemical releases...
Insurers can no longer reject customers with expensive medical conditions thanks to the health...
Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen...
The market for test and pharmaceutical pairs, known as companion diagnostics in the testing industry, has grown significantly. The global companion diagnostic market is valued at about $1.2 billion for 2013. This is up from $950 million in 2011, an increase of 12.5%.
Acura Pharmaceuticals has been awarded a $300,000 grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology.
The alliance is intended to encompass a long-term supply agreement in which EMD Millipore will provide raw materials for biopharmaceutical manufacturing.
Pfizer and Merck announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer.
Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.
VIVUS today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.
Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...
Business isn't buying the Alabama Supreme Court's attempt to limit the fallout from its decision saying brand-name drugmakers can be held liable for warnings on generic medication produced by other companies. A majority of justices signed off on an opinion that went to lengths last week to say...
The prison agency in the nation's busiest death penalty state paid $13,500 for its most recent batch of pentobarbital at a cost of $1,500 per vial, compared to $350 per dose spent last year.
Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's® lead program, LiRIS®, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
The maker of the prostate cancer treatment Provenge said in a Securities and Exchange Commission filing that there is a "significant risk" it will not be able to repay or refinance $620 million in notes due in 2016.
A Canadian company developing an experimental Ebola drug has seen its stock swing wildly in what one analyst describes as market overreaction to the latest headlines about the deadly outbreak.
McKesson Corp. was required to ensure vaccines were maintained at proper temperatures by, among other things, setting electronic temperature monitors to detect when air temperature in the box reached certain levels.
MannKind will receive $150 million upfront and then potential milestone payments of up to $775 million, depending on whether certain regulatory, development and sales targets are met. MannKind will make the supply of Afrezza, and Sanofi will be responsible for global commercial, regulatory and development activities.
U.S. Government Exercises $18.9M Contract Option for Emergent BioSolutions' Vaccinia Immune Globulin Intravenous ProgramAugust 8, 2014 8:08 am | News | Comments
Emergent BioSolutions announced today that the Centers for Disease Control and Prevention (CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS).
Patient advocates say some insurance companies are making HIV and AIDS drugs unaffordable in plans issued through the Affordable Care Act by shifting much of the cost to customers. While the issue applies broadly to all patients with chronic illnesses that require expensive medication, HIV and AIDS advocates say they were the first to file a formal complaint with the government about pricing.
Mylan reported profit that declined by 30 percent in its second quarter, and missed analysts' expectations. The Canonsburg, Pennsylvania-based company said net income fell to $125.2 million, or 32 cents per share, from $177.7 million, or 46 cents per share.
Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses. The states' attorneys general said Wednesday that Wyeth, which Pfizer bought in 2009, trained sales representatives to prescribe Rapamune for uses other than preventing rejection of transplanted kidneys.
In 2005 I had raised a question about Batch or a Continuous Process: A Choice. At that time it seemed like a logical question and still is. However, I left part of the question unanswered. Missing was the discussion of components of pharma manufacturing, API manufacture and their formulations.
Impax Laboratories, today reported total revenues increased 45.1% to $188.1 million for the second quarter ended June 30, 2014, compared to $129.6 million in the prior year period.
Alvogen announced today that it has acquired Dream Pharma in South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea.
Walgreens today said it has exercised its option to complete the second step of its strategic transaction with Alliance Boots GmbH ahead of the original option period, which was between February and August 2015. The transaction, subject to shareholder and various regulatory approvals, would fully combine the two companies to form the first global pharmacy-led, health and wellbeing enterprise.
The Obama administration is looking for steps it could take on its own to prevent American companies from reincorporating overseas to shirk U.S. taxes, aiming to sidestep a logjam in Congress, officials said Tuesday. President Barack Obama has denounced so-called tax inversions as unpatriotic and has urged Congress to stop them.
Zoetis Inc. (ZTS) on Tuesday reported profit that rose by 6.3 percent in its second quarter, and fell short of analysts' expectations. The Florham Park, New Jersey-based company said earnings increased to $136 million, or 27 cents per share, from $128 million, or 26 cents per share, in the same quarter a year ago.
- Page 1